Clinical Trials Logo

Clinical Trial Summary

This Phase I double blind, randomized clinical study to evaluate the safety of human milk oligosaccharides (HMO) is designed to assess the safety and dosage ranging of PBCLN-003 in adults with Clostridium difficile-associated diarrhea (CDAD). Within 3 dose cohort, subjects will be randomized in a 3:1 ratio to receive PBCLN-003 or placebo.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03793686
Study type Interventional
Source Prolacta Bioscience
Contact
Status Terminated
Phase Phase 1
Start date December 6, 2018
Completion date September 1, 2020

See also
  Status Clinical Trial Phase
Completed NCT00382304 - A Study of the Absorption of GT267-004 in Patients With Clostridium Difficile-Associated Diarrhea Phase 2
Recruiting NCT04246151 - Oral Vancomycin Versus Probiotics Versus Placebo for Prevention of Clostridium Difficile Infection in Colonized Patients Early Phase 1
Completed NCT03806803 - Multicentre Blinded Comparison of Lyophilized Sterile Fecal Filtrate to Lyophilized Fecal Microbiota Transplant in Recurrent Clostridioides Difficile Infection Phase 2
Terminated NCT00772954 - Phase I Randomized, Placebo-Controlled, Double-Blind, Dose Ranging Study, Safety, Tolerability and Immunogenicity Phase 1
Recruiting NCT04305769 - Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT) Phase 2
Completed NCT00034294 - A Study of GT160-246 Versus Vancomycin in Patients With Clostridium Difficile-Associated Diarrhea Phase 2
Recruiting NCT02200328 - Efficacy of Metronidazole Prophylaxis Against Clostridium Difficile-Associated Diarrhea in High Risk Adult Patients Phase 4
Recruiting NCT03141775 - Incidence and Economic Burden of Clostridium Difficile Infections (CDI) in the German Health Care System (IBIS) N/A